We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Biomarker-Based Approach Could Identify Early Risk of Pancreatic Cancer

By LabMedica International staff writers
Posted on 20 Mar 2023
Print article
Image: Biomarkers have shown promise for identifying early risk of pancreatic cancer (Photo courtesy of Pexels)
Image: Biomarkers have shown promise for identifying early risk of pancreatic cancer (Photo courtesy of Pexels)

The incidence of pancreatic cancer is increasing, although the cause of its growing prevalence remains unknown. Even if pancreatic cancer is detected in its early stages, it usually spreads cells throughout the body, leading to an elevated risk of recurrence. While the majority of precancerous cysts known as intraductal papillary mucinous neoplasms (IPMNs) do not progress to pancreatic cancer, existing diagnostic evaluations - comprising clinical, radiographic, laboratory, endoscopic, and cytologic analyses - exhibit an overall accuracy of about 60%. Earlier, less precise methods of characterizing IPMNs have failed to identify reliable cancer markers. Now, researchers have discovered a set of biomarkers that may help understand whether cysts on the pancreas are likely to remain benign or develop into cancer.

The discovery by a research team at Duke Health (Durham, NC, USA) is a crucial first step towards establishing a clinical method for classifying lesions on the pancreas that have the maximum risk of turning cancerous, allowing for their removal before they can start spreading. If the biomarker-based approach is successful, it could help overcome the biggest obstacle in reducing the risk of developing pancreatic cancer, which is rising and grows silently before being diagnosed usually during abdominal scans.

By using digital spatial profiling, it is possible to selectively analyze individual groups of cells. This approach was adopted by Duke researchers, allowing them to identify several genetic mutations that both promote and suppress the progression of pancreatic cancer. Additionally, they identified markers capable of distinguishing between two primary variants of IPMN, as well as found distinct markers for defining a third variant that usually results in less severe disease. Some studies have inferred that inflammation contributes significantly to pancreatic cancer development. A clinical trial being conducted at Duke aims to determine whether anti-inflammatory therapy can reduce cancer progression in IPMN patients.

“Most IPMNs will never progress to pancreas cancer, but by distinguishing which ones will progress, we are creating an opportunity to prevent an incurable disease from developing,” said senior author Peter Allen, M.D., chief of the Division of Surgical Oncology at in the Department of Surgery at Duke University School of Medicine. “We found very distinct markers for high-grade cell abnormalities, as well as for slow-growing subtypes. Our work now is focusing on finding it in the cyst fluid. If we can identify these unique markers in cyst fluid, it could provide the basis for a protein biopsy that would guide whether we should remove the cyst before cancer develops and spreads.”

Related Links:
Duke Health 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.